Mizuho Adjusts PT on BioXcel Therapeutics to $1 From $4 on Solvency Concerns, Uncertainty; Keeps Neutral Rating
Mizuho Adjusts PT on BioXcel Therapeutics to $1 From $4 on Solvency Concerns, Uncertainty; Keeps Neutral Rating
瑞穗將 BioXcel Therapeutics 的目標股價從 4 美元調低至 1 美元，因爲擔心公司的償債能力和不確定性；保持其中立評級。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊